RFK Jr. Is Trump's Pick for HHS Secretary

Kebilidi is a one-time gene therapy administered directly to the brain in patients with AADC deficiency, rare genetic disorder.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction Act price negotiation timelines, the researchers say.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

Patients with metastatic non-small cell lung cancer, even those with brain metastases, experienced improved longer-term clinical outcomes while on the Opdivo/Yervoy combination compared with those patients receiving chemotherapy alone.